Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)
Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –
Innoviva operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Innoviva's operating cash flow for the twelve months ending Sep 30, 2026 was $183.47M, down 9.0% year over year. For fiscal 2025 it was $196.93M, up 4.4% from the year before. Over ten years it grew 34.5% a year on average. The highest annual figure on record is $363.81M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.93M | +4.4% |
| FY2024 | Dec 31, 2024 | $188.69M | +33.8% |
| FY2023 | Dec 31, 2023 | $141.06M | -30.1% |
| FY2022 | Dec 31, 2022 | $201.73M | -44.6% |
| FY2021 | Dec 31, 2021 | $363.81M | +16.2% |
| FY2020 | Dec 31, 2020 | $313.11M | +21.6% |
| FY2019 | Dec 31, 2019 | $257.46M | +15.2% |
| FY2018 | Dec 31, 2018 | $223.53M | +57.7% |
| FY2017 | Dec 31, 2017 | $141.75M | +132.4% |
| FY2016 | Dec 31, 2016 | $60.98M | +502.0% |
| FY2015 | Dec 31, 2015 | $10.13M | – |
| FY2014 | Dec 31, 2014 | -$130.72M | – |
| FY2013 | Dec 31, 2013 | -$129.60M | – |
| FY2012 | Dec 31, 2012 | -$127.51M | – |
| FY2011 | Dec 31, 2011 | -$88.34M | – |
| FY2010 | Dec 31, 2010 | -$75.14M | – |
| FY2009 | Dec 31, 2009 | -$58.06M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $41.70M | -16.1% |
| Q2 FY2026 | Jun 30, 2026 | $51.97M | +17.9% |
| Q1 FY2026 | Mar 31, 2026 | $35.28M | -27.4% |
| Q4 FY2025 | Dec 31, 2025 | $54.51M | -8.0% |
| Q3 FY2025 | Sep 30, 2025 | $49.73M | +2.1% |
| Q2 FY2025 | Jun 30, 2025 | $44.07M | +0.8% |
| Q1 FY2025 | Mar 31, 2025 | $48.62M | +31.2% |
| Q4 FY2024 | Dec 31, 2024 | $59.24M | +78.1% |
| Q3 FY2024 | Sep 30, 2024 | $48.69M | +10.8% |
| Q2 FY2024 | Jun 30, 2024 | $43.72M | +14.5% |
| Q1 FY2024 | Mar 31, 2024 | $37.05M | +44.2% |
| Q4 FY2023 | Dec 31, 2023 | $33.26M | +273.7% |
| Q3 FY2023 | Sep 30, 2023 | $43.94M | +180.1% |
| Q2 FY2023 | Jun 30, 2023 | $38.18M | -51.7% |
| Q1 FY2023 | Mar 31, 2023 | $25.68M | -73.8% |
| Q4 FY2022 | Dec 31, 2022 | $8.90M | -91.0% |
| Q3 FY2022 | Sep 30, 2022 | $15.69M | -83.8% |
| Q2 FY2022 | Jun 30, 2022 | $79.04M | -6.6% |
| Q1 FY2022 | Mar 31, 2022 | $98.10M | +16.6% |
| Q4 FY2021 | Dec 31, 2021 | $98.38M | +15.4% |
| Q3 FY2021 | Sep 30, 2021 | $96.71M | +29.7% |
| Q2 FY2021 | Jun 30, 2021 | $84.61M | +6.0% |
| Q1 FY2021 | Mar 31, 2021 | $84.11M | +14.5% |
| Q4 FY2020 | Dec 31, 2020 | $85.28M | +27.5% |
| Q3 FY2020 | Sep 30, 2020 | $74.56M | +29.9% |
| Q2 FY2020 | Jun 30, 2020 | $79.79M | +41.2% |
| Q1 FY2020 | Mar 31, 2020 | $73.48M | -4.1% |
| Q4 FY2019 | Dec 31, 2019 | $66.91M | +8.3% |
| Q3 FY2019 | Sep 30, 2019 | $57.40M | -4.5% |
| Q2 FY2019 | Jun 30, 2019 | $56.50M | +9.2% |
| Q1 FY2019 | Mar 31, 2019 | $76.66M | +53.6% |
| Q4 FY2018 | Dec 31, 2018 | $61.78M | +29.1% |
| Q3 FY2018 | Sep 30, 2018 | $60.12M | +38.2% |
| Q2 FY2018 | Jun 30, 2018 | $51.73M | +128.5% |
| Q1 FY2018 | Mar 31, 2018 | $49.91M | +79.8% |
| Q4 FY2017 | Dec 31, 2017 | $47.86M | +127.0% |
| Q3 FY2017 | Sep 30, 2017 | $43.49M | – |
| Q2 FY2017 | Jun 30, 2017 | $22.64M | – |
| Q1 FY2017 | Mar 31, 2017 | $27.76M | – |
| Q4 FY2016 | Dec 31, 2016 | $21.09M | – |
See a number that looks wrong?